Dai L J, Quamme G A
Department of Medicine, University of British Columbia, University Hospital, Vancouver, Canada.
J Clin Invest. 1991 Oct;88(4):1255-64. doi: 10.1172/JCI115429.
Magnesium reabsorption and regulation within the kidney occur principally within the cortical thick ascending limb (cTAL) cells of the loop of Henle. Fluorometry with the dye, mag-fura-2, was used to characterize intracellular Mg2+ concentration ([Mg2+]i) in single cTAL cells. Primary cell cultures were prepared from porcine kidneys using a double antibody technique (goat anti-human Tamm-Horsfall and rabbit anti-goat IgG antibodies). Basal [Mg2+]i was 0.52 +/- 0.02 mM, which was approximately 2% of the total cellular Mg. Cells cultured (16 h) in high magnesium media (5 mM) maintained basal [Mg2+]i, 0.48 +/- 0.02, in the normal range. However, cells cultured in nominally magnesium-free media possessed [Mg2+]i, 0.27 +/- 0.01 mM, which was associated with a significant increase in net Mg transport, (control, 0.19 +/- 0.03 and low Mg, 0.35 +/- 0.01 nmol.mg-1 protein.min-1) as assessed by 28Mg uptake. Mg(2+)-depleted cells were subsequently placed in high Mg solution (5 mM) and the Mg2+ refill rate was assessed by fluorescence. [Mg2+]i returned to normal basal levels, 0.53 +/- 0.03 mM, with a refill rate of 257 +/- 37 nM/s. Mg2+ entry was not changed by 5.0 mM Ca2+ or 2 mM Sr2+, Cd2+, Co2+, nor Ba2+ but was inhibited by Mn2+ approximately La3+ approximately Gd3+ approximately Zn2+ approximately Be2+ at 2 mM. Intracellular Ca2+ and 45Ca uptake was not altered by Mg depletion or Mg2+ refill, indicating that the entry is relatively specific to Mg2+. Mg2+ uptake was inhibited by nifedipine (117 +/- 20 nM/s), verapamil (165 +/- 34 nM/s), and diltiazem (194 +/- 19 nM/s) but enhanced by the dihydropyridine analogue, Bay K 8644 (366 +/- 71 nM/s). These antagonists and agonists were reversible with removal and [Mg2+]i subsequently returned to normal basal levels. Mg2+ entry rate was concentration and voltage dependent and maximally stimulated after 4 h in magnesium-free media. Cellular magnesium depletion results in increases in a Mg2+ refill rate which is dependent, in part, on de novo protein synthesis. These data provide evidence for novel Mg2+ entry pathways in cTAL cells which are specific for Mg2+ and highly regulated. These entry pathways are likely involved with renal Mg2+ homeostasis.
肾脏内镁的重吸收和调节主要发生在髓袢升支粗段(cTAL)细胞中。使用染料镁荧光素-2进行荧光测定,以表征单个cTAL细胞内的镁离子浓度([Mg2+]i)。采用双抗体技术(山羊抗人Tamm-Horsfall抗体和兔抗山羊IgG抗体)从猪肾制备原代细胞培养物。基础[Mg2+]i为0.52±0.02 mM,约占细胞总镁含量的2%。在高镁培养基(5 mM)中培养(16小时)的细胞维持基础[Mg2+]i在正常范围内,为0.48±0.02 mM。然而,在名义上无镁的培养基中培养的细胞,其[Mg2+]i为0.27±0.01 mM,这与通过28Mg摄取评估的净镁转运显著增加有关(对照组为0.1 /span>9±0.03,低镁组为0.35±0.01 nmol·mg-1蛋白质·min-1)。随后将缺镁的细胞置于高镁溶液(5 mM)中,并通过荧光评估镁离子再填充率。[Mg2+]i恢复到正常基础水平,为0.53±0.03 mM,再填充率为257±37 nM/s。5.0 mM的Ca2+、2 mM的Sr2+、Cd2+、Co2+或Ba2+不会改变镁离子的进入,但2 mM的Mn2+、La3+、Gd3+、Zn2+或Be2+会抑制镁离子的进入。缺镁或镁离子再填充不会改变细胞内钙离子和45Ca的摄取,表明这种进入对镁离子具有相对特异性。硝苯地平(117±20 nM/s)、维拉帕米(165±34 nM/s)和地尔硫䓬(194±19 nM/s)会抑制镁离子的摄取,但二氢吡啶类似物Bay K 8644(366±71 nM/s)会增强镁离子的摄取。去除这些拮抗剂和激动剂后作用是可逆的,随后[Mg2+]i恢复到正常基础水平。镁离子进入速率与浓度和电压有关,在无镁培养基中培养4小时后受到最大刺激。细胞内镁的消耗会导致镁离子再填充率增加,这部分取决于从头合成蛋白质。这些数据为cTAL细胞中新型的镁离子进入途径提供了证据,这些途径对镁离子具有特异性且受到高度调节。这些进入途径可能与肾脏镁离子稳态有关。